-+ 0.00%
-+ 0.00%
-+ 0.00%

Mabwell H1 FY26 loss narrows 5.08% to RMB 524.2 million; revenue more than doubled to RMB 312.45 million

PUBT·09/04/2026 13:13:22
Listen to the news
Mabwell H1 FY26 loss narrows 5.08% to RMB 524.2 million; revenue more than doubled to RMB 312.45 million
  • Mabwell posted revenue of RMB 312.45 million, more than doubled from a year earlier.
  • Net loss narrowed to RMB 524.2 million; loss per share improved to RMB 1.26.
  • Total assets climbed to RMB 5.29 billion; equity nearly doubled to RMB 1.05 billion.
  • Completed placement of 47,130,200 new H shares, raising net proceeds of about HKD 1.2 billion for R&D and working capital.
  • Advanced pipeline led by 9MW2821, with Phase III interim analyses in urothelial and cervical cancer planned in H2 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mabwell (Shanghai) Bioscience Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260904-12322070), on September 04, 2026, and is solely responsible for the information contained therein.